3 news items
InflaRx Hosts R&D Event Highlighting the Promise of INF904
IFRX
5 Jun 24
Commercial assessment indicates CSU and HS both represent multi-billion-dollar market opportunities, with tremendous patient need for effective new
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
IFRX
21 May 24
at ATS 2024 is comprised of 71 patients from PANAMO that assessed 28- and 60-day all-cause mortality in the subgroup of patients taking the combination
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX
8 May 24
trial enrolling CSU and HS patients is expected to begin by the end of 2024 and to assess safety, as well as PK and PD parameters. InflaRx anticipates
- Prev
- 1
- Next